U.S. FDA Clears Terumo Blood and Cell Technologies’ New Plasma Collection Technology
By: Colorado BioScience Association Date: 03/16/2022
The U.S. Food and Drug Administration (FDA) cleared the new plasma collection system developed by Terumo Blood and Cell Technologies (Terumo BCT), a medical technology company. Rika is a next-generation automated technology focused on the experience of plasma center employees and donors. It includes safety features to minimize operator errors and collects plasma in 35 minutes or less. Rika will debut this spring in a limited market release at CSL Plasma collection centers in the Denver, Colorado area. Plans are underway for rollout at additional CSL Plasma centers in 2022.
Rika was developed in response to the industry’s need for technological advancement and process improvements to drive efficiency and quality while maintaining donor safety and a sufficient plasma supply.
Investing in the source plasma industry is a natural evolution in the Terumo Blood and Cell Technologies portfolio given its experience and leadership in apheresis technology. The company spends three times more than the industry average in development as an innovation partner to customers globally.
Find out more in the press release.